Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Proteinuria: later-stage trial registry
5 of 11 indexed Proteinuria trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Proteinuria: 11 US clinical trials tracked, 5 recruiting.
Proteinuria is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 2 of these trials.
Enrollment posture brief
Registry condition proteinuria
OPEN 5 | RECR 45% | LATE 5 | EARLY 2 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Breast Carcinoma (45% recruiting · 11 trials)
Proteinuria lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Proteinuria on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Proteinuria recruits in line with its size-band peers.
5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Proteinuria research.
Bayer accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Proteinuria trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.
-
Proteinuria splits between interventional and observational designs.
7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Bayer
NCT05196035
Proteinuria in Pre and Post Transplant
University of Miami
NCT01094327
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Bayer
NCT05457283
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00977977
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Travere Therapeutics
NCT07219121
Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery?
NYU Langone Health
NCT02798042
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Albert Einstein College of Medicine
NCT01029002
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
University of Alabama at Birmingham
NCT00446862
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Mayo Clinic
NCT02282930
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
Brigham and Women's Hospital
NCT02327403
Antiproteinuric Agents and Fabry Disease
University of Alabama at Birmingham
NCT00343577
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Proteinuria records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Proteinuria trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Proteinuria page
11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Proteinuria trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bayer sponsors the most Proteinuria trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Proteinuria condition card totals 11 registered trials; most-linked intervention Finerenone (Kerendia, BAY94-8862); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.